The Contentious Biosimilar Nonproprietary Naming Debate
In the five years since the Biologics Price Competition and Innovation Act (BPCIA) was enacted into law, stakeholders have been hard at work fleshing out how the new product category of...To view the full article, register now.
Already a subscriber? Click here to view full article